Biomarkers of cholestasis
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward...
Gespeichert in:
| Veröffentlicht in: | Biomarkers in medicine 2021-04, Vol.15 (6), p.437-454 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 454 |
|---|---|
| container_issue | 6 |
| container_start_page | 437 |
| container_title | Biomarkers in medicine |
| container_volume | 15 |
| creator | Pieters, Alanah Gijbels, Eva Cogliati, Bruno Annaert, Pieter Devisscher, Lindsey Vinken, Mathieu |
| description | Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks. |
| doi_str_mv | 10.2217/bmm-2020-0691 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_bmm_2020_0691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33709780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-ce528f03e43f76b073b99d8f65dfde5be1a73912e33fb6a881188b458bf4f8b83</originalsourceid><addsrcrecordid>eNp1jz1PwzAQhi0EoqUwMrCg_gHD2Y6_Rqj4kiqxwGzFzlkYmqayk4F_T6pAN6a7k5731T2EXDK44ZzpW9-2lAMHCsqyIzJnWnIKQrPjw67EjJyV8gkgtVb8lMyE0GC1gTm5uk9dW-cvzGXZxWX46DZY-rqkck5OYr0pePE7F-T98eFt9UzXr08vq7s1DcLwngaU3EQQWImolQctvLWNiUo2sUHpkdVaWMZRiOhVbQxjxvhKGh-raLwRC0Kn3pC7UjJGt8tpfOnbMXB7RTcqur2i2yuO_PXE7wbfYnOg_5xGwE5AHPohYwkJtwHddI2JFNIW_yn_Acv-Xuo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biomarkers of cholestasis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Pieters, Alanah ; Gijbels, Eva ; Cogliati, Bruno ; Annaert, Pieter ; Devisscher, Lindsey ; Vinken, Mathieu</creator><creatorcontrib>Pieters, Alanah ; Gijbels, Eva ; Cogliati, Bruno ; Annaert, Pieter ; Devisscher, Lindsey ; Vinken, Mathieu</creatorcontrib><description>Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.</description><identifier>ISSN: 1752-0363</identifier><identifier>EISSN: 1752-0371</identifier><identifier>DOI: 10.2217/bmm-2020-0691</identifier><identifier>PMID: 33709780</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Animals ; biomarker ; Biomarkers - metabolism ; cholestasis ; Cholestasis - diagnosis ; Cholestasis - metabolism ; Humans ; liver ; Liver - metabolism ; Liver - pathology ; Liver Diseases - diagnosis ; Liver Diseases - metabolism ; omics</subject><ispartof>Biomarkers in medicine, 2021-04, Vol.15 (6), p.437-454</ispartof><rights>2021 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-ce528f03e43f76b073b99d8f65dfde5be1a73912e33fb6a881188b458bf4f8b83</citedby><cites>FETCH-LOGICAL-c382t-ce528f03e43f76b073b99d8f65dfde5be1a73912e33fb6a881188b458bf4f8b83</cites><orcidid>0000-0001-9730-952X ; 0000-0003-4862-9580 ; 0000-0003-3525-7351 ; 0000-0001-5115-8893 ; 0000-0002-7366-0769 ; 0000-0002-1388-7240</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33709780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pieters, Alanah</creatorcontrib><creatorcontrib>Gijbels, Eva</creatorcontrib><creatorcontrib>Cogliati, Bruno</creatorcontrib><creatorcontrib>Annaert, Pieter</creatorcontrib><creatorcontrib>Devisscher, Lindsey</creatorcontrib><creatorcontrib>Vinken, Mathieu</creatorcontrib><title>Biomarkers of cholestasis</title><title>Biomarkers in medicine</title><addtitle>Biomark Med</addtitle><description>Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.</description><subject>Animals</subject><subject>biomarker</subject><subject>Biomarkers - metabolism</subject><subject>cholestasis</subject><subject>Cholestasis - diagnosis</subject><subject>Cholestasis - metabolism</subject><subject>Humans</subject><subject>liver</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Diseases - diagnosis</subject><subject>Liver Diseases - metabolism</subject><subject>omics</subject><issn>1752-0363</issn><issn>1752-0371</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1jz1PwzAQhi0EoqUwMrCg_gHD2Y6_Rqj4kiqxwGzFzlkYmqayk4F_T6pAN6a7k5731T2EXDK44ZzpW9-2lAMHCsqyIzJnWnIKQrPjw67EjJyV8gkgtVb8lMyE0GC1gTm5uk9dW-cvzGXZxWX46DZY-rqkck5OYr0pePE7F-T98eFt9UzXr08vq7s1DcLwngaU3EQQWImolQctvLWNiUo2sUHpkdVaWMZRiOhVbQxjxvhKGh-raLwRC0Kn3pC7UjJGt8tpfOnbMXB7RTcqur2i2yuO_PXE7wbfYnOg_5xGwE5AHPohYwkJtwHddI2JFNIW_yn_Acv-Xuo</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Pieters, Alanah</creator><creator>Gijbels, Eva</creator><creator>Cogliati, Bruno</creator><creator>Annaert, Pieter</creator><creator>Devisscher, Lindsey</creator><creator>Vinken, Mathieu</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-9730-952X</orcidid><orcidid>https://orcid.org/0000-0003-4862-9580</orcidid><orcidid>https://orcid.org/0000-0003-3525-7351</orcidid><orcidid>https://orcid.org/0000-0001-5115-8893</orcidid><orcidid>https://orcid.org/0000-0002-7366-0769</orcidid><orcidid>https://orcid.org/0000-0002-1388-7240</orcidid></search><sort><creationdate>20210401</creationdate><title>Biomarkers of cholestasis</title><author>Pieters, Alanah ; Gijbels, Eva ; Cogliati, Bruno ; Annaert, Pieter ; Devisscher, Lindsey ; Vinken, Mathieu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-ce528f03e43f76b073b99d8f65dfde5be1a73912e33fb6a881188b458bf4f8b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>biomarker</topic><topic>Biomarkers - metabolism</topic><topic>cholestasis</topic><topic>Cholestasis - diagnosis</topic><topic>Cholestasis - metabolism</topic><topic>Humans</topic><topic>liver</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Diseases - diagnosis</topic><topic>Liver Diseases - metabolism</topic><topic>omics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pieters, Alanah</creatorcontrib><creatorcontrib>Gijbels, Eva</creatorcontrib><creatorcontrib>Cogliati, Bruno</creatorcontrib><creatorcontrib>Annaert, Pieter</creatorcontrib><creatorcontrib>Devisscher, Lindsey</creatorcontrib><creatorcontrib>Vinken, Mathieu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Biomarkers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pieters, Alanah</au><au>Gijbels, Eva</au><au>Cogliati, Bruno</au><au>Annaert, Pieter</au><au>Devisscher, Lindsey</au><au>Vinken, Mathieu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers of cholestasis</atitle><jtitle>Biomarkers in medicine</jtitle><addtitle>Biomark Med</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>15</volume><issue>6</issue><spage>437</spage><epage>454</epage><pages>437-454</pages><issn>1752-0363</issn><eissn>1752-0371</eissn><abstract>Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The ‘omics’ era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>33709780</pmid><doi>10.2217/bmm-2020-0691</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0001-9730-952X</orcidid><orcidid>https://orcid.org/0000-0003-4862-9580</orcidid><orcidid>https://orcid.org/0000-0003-3525-7351</orcidid><orcidid>https://orcid.org/0000-0001-5115-8893</orcidid><orcidid>https://orcid.org/0000-0002-7366-0769</orcidid><orcidid>https://orcid.org/0000-0002-1388-7240</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1752-0363 |
| ispartof | Biomarkers in medicine, 2021-04, Vol.15 (6), p.437-454 |
| issn | 1752-0363 1752-0371 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_bmm_2020_0691 |
| source | MEDLINE; PubMed Central |
| subjects | Animals biomarker Biomarkers - metabolism cholestasis Cholestasis - diagnosis Cholestasis - metabolism Humans liver Liver - metabolism Liver - pathology Liver Diseases - diagnosis Liver Diseases - metabolism omics |
| title | Biomarkers of cholestasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A28%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20of%20cholestasis&rft.jtitle=Biomarkers%20in%20medicine&rft.au=Pieters,%20Alanah&rft.date=2021-04-01&rft.volume=15&rft.issue=6&rft.spage=437&rft.epage=454&rft.pages=437-454&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217/bmm-2020-0691&rft_dat=%3Cpubmed_cross%3E33709780%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33709780&rfr_iscdi=true |